These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 31955409)

  • 1. Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open Data.
    Conrado DJ; Duvvuri S; Geerts H; Burton J; Biesdorf C; Ahamadi M; Macha S; Hather G; Francisco Morales J; Podichetty J; Nicholas T; Stephenson D; Trame M; Romero K; Corrigan B;
    Clin Pharmacol Ther; 2020 Apr; 107(4):796-805. PubMed ID: 31955409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leveraging Humanized Animal Models to Understand Human Drug Disposition: Opportunities, Challenges, and Future Directions.
    Choo EF; Salphati L
    Clin Pharmacol Ther; 2018 Feb; 103(2):188-192. PubMed ID: 29193027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Have there been improvements in Alzheimer's disease drug discovery over the past 5 years?
    Cacabelos R
    Expert Opin Drug Discov; 2018 Jun; 13(6):523-538. PubMed ID: 29607687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translational Scoring of Candidate Treatments for Alzheimer's Disease: A Systematic Approach.
    Cummings JL
    Dement Geriatr Cogn Disord; 2020; 49(1):22-37. PubMed ID: 32512572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Be open about drug failures to speed up research.
    Alteri E; Guizzaro L
    Nature; 2018 Nov; 563(7731):317-319. PubMed ID: 30425369
    [No Abstract]   [Full Text] [Related]  

  • 6. [Drug development for overcoming dementia in Japan].
    Nakamura H
    Rinsho Shinkeigaku; 2014; 54(12):1181-3. PubMed ID: 25672739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translational medicine lessons from flurizan's failure in Alzheimer's disease (AD) trial: Implication for future drug discovery and development for AD.
    Wan HI; Jacobsen JS; Rutkowski JL; Feuerstein GZ
    Clin Transl Sci; 2009 Jun; 2(3):242-7. PubMed ID: 20443898
    [No Abstract]   [Full Text] [Related]  

  • 8. AI for drug discovery is advancing rapidly: We need smart biology for it to fulfill its mission.
    Ushio M; Carpenter Z
    Drug Discov Today; 2022 Jan; 27(1):1-2. PubMed ID: 34634477
    [No Abstract]   [Full Text] [Related]  

  • 9. The future is now: model-based clinical trial design for Alzheimer's disease.
    Romero K; Ito K; Rogers JA; Polhamus D; Qiu R; Stephenson D; Mohs R; Lalonde R; Sinha V; Wang Y; Brown D; Isaac M; Vamvakas S; Hemmings R; Pani L; Bain LJ; Corrigan B; ;
    Clin Pharmacol Ther; 2015 Mar; 97(3):210-4. PubMed ID: 25669145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Have nanomedicines progressed as much as we'd hoped for in drug discovery and development?
    Sarmento B
    Expert Opin Drug Discov; 2019 Aug; 14(8):723-725. PubMed ID: 31161834
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeting apolipoprotein E for treating Alzheimer's disease.
    Bales KR; Paul SM
    Neurosci Lett; 2019 Sep; 709():134366. PubMed ID: 31336138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strengthening the Case for Epilepsy Drug Development: Bridging Experiences from the Alzheimer's Disease Field-An Opinion.
    Twyman RE
    Neurochem Res; 2017 Jul; 42(7):2099-2115. PubMed ID: 28589521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developments with multi-target drugs for Alzheimer's disease: an overview of the current discovery approaches.
    González JF; Alcántara AR; Doadrio AL; Sánchez-Montero JM
    Expert Opin Drug Discov; 2019 Sep; 14(9):879-891. PubMed ID: 31165654
    [No Abstract]   [Full Text] [Related]  

  • 14. Alzheimer's disease drug development: old problems require new priorities.
    Becker RE; Greig NH
    CNS Neurol Disord Drug Targets; 2008 Dec; 7(6):499-511. PubMed ID: 19128207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to address the complexity of multi-targeted drug discovery for Alzheimer's disease?
    González JF; Sánchez-Montero JM
    Expert Opin Drug Discov; 2024 Oct; 19(10):1149-1152. PubMed ID: 39075884
    [No Abstract]   [Full Text] [Related]  

  • 16. Editorial: Alzheimer's Disease Drug Development Pipeline 2020.
    Sabbagh MN
    J Prev Alzheimers Dis; 2020; 7(2):66-67. PubMed ID: 32236392
    [No Abstract]   [Full Text] [Related]  

  • 17. Boosting translational research on Alzheimer's disease in Europe: The Innovative Medicine Initiative AD research platform.
    Vaudano E; Vannieuwenhuyse B; Van Der Geyten S; van der Lei J; Visser PJ; Streffer J; Ritchie C; McHale D; Lovestone S; Hofmann-Apitius M; Truyen L; Goldman M
    Alzheimers Dement; 2015 Sep; 11(9):1121-2. PubMed ID: 25754460
    [No Abstract]   [Full Text] [Related]  

  • 18. Alzheimer's disease drug development: translational neuroscience strategies.
    Cummings JL; Banks SJ; Gary RK; Kinney JW; Lombardo JM; Walsh RR; Zhong K
    CNS Spectr; 2013 Jun; 18(3):128-38. PubMed ID: 23472637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Big data to smart data in Alzheimer's disease: Real-world examples of advanced modeling and simulation.
    Haas M; Stephenson D; Romero K; Gordon MF; Zach N; Geerts H;
    Alzheimers Dement; 2016 Sep; 12(9):1022-1030. PubMed ID: 27327540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Approaches to Develop Drug Treatment for Alzheimer's Disease: Targeting Calcium Dysregulation.
    Wei H
    Curr Alzheimer Res; 2020; 17(4):311-312. PubMed ID: 32623998
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.